333 related articles for article (PubMed ID: 31562135)
1. Mutant calreticulin in myeloproliferative neoplasms.
How J; Hobbs GS; Mullally A
Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
3. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
4. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
5. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
6. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
7. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
Brooks SA; Kim DM; Morse SJ; Nguyen QH; Craver BM; Lai HY; Fleischman AG
Leuk Res; 2019 Jul; 82():11-14. PubMed ID: 31128484
[No Abstract] [Full Text] [Related]
10. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
11. Mutant calreticulin: when a chaperone becomes intrusive.
Cazzola M
Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
[TBL] [Abstract][Full Text] [Related]
12. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CALR interactome in myeloproliferative neoplasms.
Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
[TBL] [Abstract][Full Text] [Related]
14. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Araki M; Komatsu N
Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
[TBL] [Abstract][Full Text] [Related]
15. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
16. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
17. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
18. The role of calreticulin mutations in myeloproliferative neoplasms.
Araki M; Komatsu N
Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
Patterson-Fortin J; Moliterno AR
Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
[TBL] [Abstract][Full Text] [Related]
20. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
